Commercial partners

ImClone Systems (a subsidiary of Eli Lilly) – developer of anti-VEGFR-3 antibody drug for treatment of cancer.

Ark Therapeutics – developer of Trinam® for vascular access grafts.

Scientific collaborators

Circadian collaborates with some of the world’s most renowned researchers in the field of angiogenesis and lymphangiogenesis.

Laboratory of Prof. Kari Alitalo, University of Helsinki – discoverer of VEGFR-3 and its ligand VEGF-C.

Laboratory of Profs. Steve Stacker and Marc Achen, Ludwig Institute for Cancer Research – discoverers of the VEGFR-3 ligand VEGF-D.

New partnership opportunities

For partnership interest in any Circadian program, please email info@circadian.com.au or call +61 3 9826 0399.